Trial Profile
A clinical study of a replication-competent, recombinant herpes simplex virus type 1 (G47delta) in patients with progressive malignant pleural mesothelioma
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 13 Sep 2021
Price :
$35
*
At a glance
- Drugs Teserpaturev (Primary)
- Indications Malignant-mesothelioma
- Focus Adverse reactions
- 09 Sep 2021 Status changed from recruiting to active, no longer recruiting.
- 17 Sep 2018 New trial record